Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
February 05, 2026
Not intended for U.S. and UK Media – International Stroke Conference (ISC) 2026:
Bayer’s asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo
February 03, 2026
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives third approval in China for men with advanced prostate cancer
January 30, 2026
Not intended for U.S. and UK Media
Finerenone recommended for the treatment of patients with heart failure with LVEF ≥40% in the EU
Discover More
